Forsta AP Fonden Buys 5,900 Shares of Eli Lilly and Company (NYSE:LLY)

Forsta AP Fonden raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 216,251 shares of the company's stock after purchasing an additional 5,900 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of Forsta AP Fonden's portfolio, making the stock its 12th largest holding. Forsta AP Fonden's holdings in Eli Lilly and Company were worth $178,604,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Knightsbridge Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after acquiring an additional 15 shares during the period. LS Investment Advisors LLC boosted its stake in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the period. Prism Advisors Inc. purchased a new position in Eli Lilly and Company during the 1st quarter valued at about $207,000. CSM Advisors LLC increased its position in shares of Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after buying an additional 245 shares during the period. Finally, Hemington Wealth Management lifted its holdings in shares of Eli Lilly and Company by 14.4% in the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after buying an additional 124 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $999.50.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $640.17 on Friday. The company has a market capitalization of $606.71 billion, a P/E ratio of 52.09, a PEG ratio of 1.06 and a beta of 0.44. Eli Lilly and Company has a fifty-two week low of $633.20 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The stock has a 50 day moving average price of $776.36 and a two-hundred day moving average price of $799.60.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.92 EPS. Analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.